Pancreatic Cancer Research

ResearcherCharles UniversityActive in the last 2 years

Martin Oliverius

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8649-3824; OpenAlex author ID A5028686295. Sources: OpenAlex.

Their work

Papers
34 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 7 papers · 2022: 2 papers · 2023: 5 papers · 2024: 6 papers · 2025: 3 papers · 2026: 1 paper

Papers 34

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  4. Determinants of Implantation Success in Pancreatic Cancer Patient-Derived Xenografts: Role of Matrigel Application, Histological Subtype, and Time Management. Last author DOI 10.14712/fb2025.0006↗
  5. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  6. Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2024.109044↗
  7. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  8. Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience. Co-author DOI 10.21873/invivo.13758↗
  9. Pancreatic surgery at the University Hospital Kralovske Vinohrady: 10-year review with a survival analysis for pancreatic ductal adenocarcinoma. Last author DOI 10.33699/pis.2024.103.4.132-137↗
  10. Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pan… Co-author DOI 10.3390/biomedicines12050962↗
  11. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  12. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  13. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  14. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  15. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  16. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  17. Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens Last author DOI 10.33699/pis.2022.101.12.584-592↗
  18. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  19. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  20. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  21. Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review. Co-author DOI 10.21873/invivo.12229↗
  22. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  23. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  24. Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer. Co-author DOI 10.3892/ol.2021.12859↗
  25. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  26. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. Co-author DOI 10.1093/mutage/gez021↗
  27. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  28. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  29. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
  30. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass. Co-author DOI 10.3748/wjg.v23.i12.2185↗
  31. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  32. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  33. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Co-author DOI 10.1007/s00280-013-2246-2↗
  34. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Co-author DOI 10.1097/mpa.0b013e318279b861↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pavel Souček · 12 shared papers, 2013–2025 · strength 1.13
  2. Árpád Szabó · 5 shared papers, 2021–2025 · strength 0.93
  3. Tomas Sychra · 4 shared papers, 2022–2025 · strength 0.86
  4. R Gürlich · 3 shared papers, 2021–2024 · strength 0.62
  5. Beatrice Mohelníková-Duchoňová · 9 shared papers, 2013–2022 · strength 0.58
  6. Renata Soumarová · 2 shared papers, 2021–2024 · strength 0.47
  7. Marián Liberko · 2 shared papers, 2021–2024 · strength 0.47
  8. Zdeněk Kala · 6 shared papers, 2013–2021 · strength 0.35
  9. Adam Whitley · 1 shared paper, 2024 · strength 0.31
  10. Emin Gayibov · 1 shared paper, 2025 · strength 0.22
  11. Václav Mandys · 1 shared paper, 2024 · strength 0.22
  12. Jan Hrudka · 1 shared paper, 2024 · strength 0.22
  13. Alexey Popov · 1 shared paper, 2024 · strength 0.22
  14. Viktor Hlaváč · 3 shared papers, 2013–2019 · strength 0.18
  15. Maria Gazouli · 3 shared papers, 2016–2022 · strength 0.18
  16. Federico Canzian · 3 shared papers, 2016–2022 · strength 0.18
  17. Renata Talar‐Wojnarowska · 3 shared papers, 2016–2022 · strength 0.18
  18. Gabriele Capurso · 3 shared papers, 2016–2022 · strength 0.18
  19. Daniele Campa · 3 shared papers, 2016–2022 · strength 0.18
  20. Francesca Tavano · 3 shared papers, 2016–2022 · strength 0.18
  21. Raffaele Pezzilli · 3 shared papers, 2016–2022 · strength 0.18
  22. Radmila Lemstrová · 3 shared papers, 2017 · strength 0.15
  23. David J. Hughes · 3 shared papers, 2017 · strength 0.15
  24. Jan Hlavsa · 3 shared papers, 2013–2017 · strength 0.14
  25. Ľudmila Vodičková · 2 shared papers, 2017–2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.